EdgarLookup

GRACO INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that GRACO INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
23.3%
Profit Margin
Net income ÷ revenue
15.9%
Return on Assets
Net income ÷ assets
+5.8%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $2.24B Feb 17, 2026
FY2025 Dec 27, 2024 $2.11B Feb 17, 2026
FY2025 Dec 29, 2023 $2.20B Feb 17, 2026
FY2024 Dec 30, 2022 $2.14B Feb 18, 2025
FY2023 Dec 31, 2021 $1.99B Feb 20, 2024
FY2020 Dec 25, 2020 $470.34M Feb 16, 2021
FY2020 Sep 25, 2020 $439.32M Feb 16, 2021
FY2020 Jun 26, 2020 $366.89M Feb 16, 2021
FY2020 Mar 27, 2020 $373.57M Feb 16, 2021
FY2020 Dec 27, 2019 $412.29M Feb 16, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 29, 2017 $374.86M Apr 23, 2018
FY2017 Sep 29, 2017 $379.81M Apr 23, 2018
FY2017 Jun 30, 2017 $379.48M Apr 23, 2018
FY2017 Mar 31, 2017 $340.59M Apr 23, 2018
FY2017 Dec 30, 2016 $349.06M Apr 23, 2018
FY2017 Sep 23, 2016 $327.19M Apr 23, 2018
FY2017 Jun 24, 2016 $348.13M Apr 23, 2018
FY2017 Mar 25, 2016 $304.91M Apr 23, 2018
FY2016 Dec 25, 2015 $325.56M Feb 21, 2017
FY2016 Sep 25, 2015 $318.99M Feb 21, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $1.17B Feb 17, 2026
FY2025 Dec 27, 2024 $1.12B Feb 17, 2026
FY2025 Dec 29, 2023 $1.16B Feb 17, 2026
FY2024 Dec 30, 2022 $1.06B Feb 18, 2025
FY2023 Dec 31, 2021 $1.03B Feb 20, 2024
FY2020 Dec 25, 2020 $244.82M Feb 16, 2021
FY2020 Sep 25, 2020 $228.95M Feb 16, 2021
FY2020 Jun 26, 2020 $182.53M Feb 16, 2021
FY2020 Mar 27, 2020 $198.63M Feb 16, 2021
FY2020 Dec 27, 2019 $209.38M Feb 16, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $521.84M Feb 17, 2026
FY2025 Dec 27, 2024 $486.08M Feb 17, 2026
FY2025 Dec 29, 2023 $506.51M Feb 17, 2026
FY2024 Dec 30, 2022 $460.65M Feb 18, 2025
FY2023 Dec 31, 2021 $439.87M Feb 20, 2024
FY2022 Dec 25, 2020 $330.46M Feb 21, 2023
FY2021 Dec 27, 2019 $343.85M Feb 22, 2022
FY2020 Dec 28, 2018 $341.05M Feb 16, 2021
FY2019 Dec 29, 2017 $252.41M Feb 18, 2020
FY2018 Dec 30, 2016 $40.67M Feb 19, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $624.80M Feb 17, 2026
FY2025 Dec 27, 2024 $570.10M Feb 17, 2026
FY2025 Dec 29, 2023 $646.84M Feb 17, 2026
FY2024 Dec 30, 2022 $572.70M Feb 18, 2025
FY2023 Dec 31, 2021 $531.32M Feb 20, 2024
FY2022 Dec 25, 2020 $391.72M Feb 21, 2023
FY2021 Dec 27, 2019 $424.46M Feb 22, 2022
FY2020 Dec 28, 2018 $436.43M Feb 16, 2021
FY2019 Dec 29, 2017 $378.75M Feb 18, 2020
FY2018 Dec 30, 2016 $121.14M Feb 19, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $82.30M Feb 17, 2026
FY2025 Dec 27, 2024 $87.23M Feb 17, 2026
FY2025 Dec 29, 2023 $82.82M Feb 17, 2026
FY2024 Dec 30, 2022 $80.01M Feb 18, 2025
FY2023 Dec 31, 2021 $79.65M Feb 20, 2024
FY2022 Dec 25, 2020 $72.19M Feb 21, 2023
FY2021 Dec 27, 2019 $67.56M Feb 22, 2022
FY2020 Dec 28, 2018 $63.12M Feb 16, 2021
FY2019 Dec 29, 2017 $59.22M Feb 18, 2020
FY2018 Dec 30, 2016 $59.57M Feb 19, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $683.59M Feb 17, 2026
FY2025 Dec 27, 2024 $621.70M Feb 17, 2026
FY2025 Dec 29, 2023 $651.02M Feb 17, 2026
FY2024 Dec 30, 2022 $377.39M Feb 18, 2025
FY2023 Dec 31, 2021 $456.90M Feb 20, 2024
FY2022 Dec 25, 2020 $394.04M Feb 21, 2023
FY2021 Dec 27, 2019 $418.73M Feb 22, 2022
FY2020 Dec 28, 2018 $367.99M Feb 16, 2021
FY2019 Dec 29, 2017 $337.86M Feb 18, 2020
FY2018 Dec 30, 2016 $276.01M Feb 19, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $45.67M Feb 17, 2026
FY2025 Dec 27, 2024 $106.74M Feb 17, 2026
FY2025 Dec 29, 2023 $184.78M Feb 17, 2026
FY2024 Dec 30, 2022 $201.16M Feb 18, 2025
FY2023 Dec 31, 2021 $133.57M Feb 20, 2024
FY2022 Dec 25, 2020 $71.34M Feb 21, 2023
FY2021 Dec 27, 2019 $127.95M Feb 22, 2022
FY2020 Dec 28, 2018 $53.85M Feb 16, 2021
FY2019 Dec 29, 2017 $40.19M Feb 18, 2020
FY2018 Dec 30, 2016 $42.11M Feb 19, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $3.27B Feb 17, 2026
FY2025 Dec 27, 2024 $3.14B Feb 17, 2026
FY2024 Dec 29, 2023 $2.72B Feb 18, 2025
FY2023 Dec 30, 2022 $2.44B Feb 20, 2024
FY2022 Dec 31, 2021 $2.44B Feb 21, 2023
FY2021 Dec 25, 2020 $1.99B Feb 22, 2022
FY2020 Dec 27, 2019 $1.69B Feb 16, 2021
FY2019 Dec 28, 2018 $1.47B Feb 18, 2020
FY2018 Dec 29, 2017 $1.39B Feb 19, 2019
FY2017 Dec 30, 2016 $1.24B Apr 23, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $2.65B Feb 17, 2026
FY2025 Dec 27, 2024 $2.58B Feb 17, 2026
FY2025 Dec 29, 2023 $2.22B Feb 17, 2026
FY2025 Dec 30, 2022 $1.86B Feb 17, 2026

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $585.30M Feb 17, 2026
FY2025 Dec 27, 2024 $487.47M Feb 17, 2026
FY2025 Dec 29, 2023 $370.23M Feb 17, 2026
FY2024 Dec 30, 2022 $368.17M Feb 18, 2025
FY2023 Dec 31, 2021 $356.26M Feb 20, 2024
FY2022 Dec 25, 2020 $347.60M Feb 21, 2023
FY2021 Dec 27, 2019 $307.66M Feb 22, 2022
FY2020 Dec 28, 2018 $293.85M Feb 16, 2021
FY2019 Dec 29, 2017 $278.79M Feb 18, 2020
FY2018 Dec 30, 2016 $259.85M Feb 19, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $1.46B Feb 17, 2026
FY2025 Dec 27, 2024 $1.51B Feb 17, 2026
FY2024 Dec 29, 2023 $1.23B Feb 18, 2025
FY2023 Dec 30, 2022 $976.85M Feb 20, 2024
FY2022 Dec 31, 2021 $876.92M Feb 21, 2023
FY2021 Dec 25, 2020 $568.30M Feb 22, 2022
FY2020 Dec 27, 2019 $448.99M Feb 16, 2021
FY2019 Dec 28, 2018 $220.73M Feb 18, 2020
FY2018 Dec 29, 2017 $181.60M Feb 19, 2019
FY2017 Dec 30, 2016 $206.82M Apr 23, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 $624.08M Feb 17, 2026
FY2025 Dec 27, 2024 $675.34M Feb 17, 2026
FY2024 Dec 29, 2023 $537.95M Feb 18, 2025
FY2023 Dec 30, 2022 $339.20M Feb 20, 2024
FY2022 Dec 31, 2021 $624.30M Feb 21, 2023
FY2021 Dec 25, 2020 $378.91M Feb 22, 2022
FY2020 Dec 27, 2019 $220.97M Feb 16, 2021
FY2019 Dec 28, 2018 $132.12M Feb 18, 2020
FY2019 Dec 29, 2017 $103.66M Feb 18, 2020
FY2018 Dec 30, 2016 $52.37M Feb 19, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 3 Feb 17, 2026
FY2025 Dec 27, 2024 2 Feb 17, 2026
FY2025 Dec 29, 2023 3 Feb 17, 2026
FY2024 Dec 30, 2022 2 Feb 18, 2025
FY2023 Dec 31, 2021 2 Feb 20, 2024
FY2020 Dec 25, 2020 0 Feb 16, 2021
FY2020 Sep 25, 2020 0 Feb 16, 2021
FY2020 Jun 26, 2020 0 Feb 16, 2021
FY2020 Mar 27, 2020 0 Feb 16, 2021
FY2020 Dec 27, 2019 0 Feb 16, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 3 Feb 17, 2026
FY2025 Dec 27, 2024 2 Feb 17, 2026
FY2025 Dec 29, 2023 2 Feb 17, 2026
FY2024 Dec 30, 2022 2 Feb 18, 2025
FY2023 Dec 31, 2021 2 Feb 20, 2024
FY2020 Dec 25, 2020 0 Feb 16, 2021
FY2020 Sep 25, 2020 0 Feb 16, 2021
FY2020 Jun 26, 2020 0 Feb 16, 2021
FY2020 Mar 27, 2020 0 Feb 16, 2021
FY2020 Dec 27, 2019 0 Feb 16, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 26, 2025 165.15M Feb 17, 2026
FY2025 Dec 27, 2024 169.39M Feb 17, 2026
FY2024 Dec 29, 2023 167.95M Feb 18, 2025
FY2023 Dec 30, 2022 167.70M Feb 20, 2024
FY2022 Jul 1, 2022 169.13M Feb 21, 2023
FY2021 Jun 25, 2021 169.66M Feb 22, 2022
FY2019 Dec 27, 2019 167.29M Feb 18, 2020
FY2019 Dec 28, 2018 165.17M Feb 18, 2020
FY2018 Dec 29, 2017 169.32M Feb 19, 2019
FY2017 Dec 30, 2016 167.50M Apr 23, 2018